IP Library › Granted Patent US 10,022,361
Granted Patent B2
US 10,022,361 · App. 14/275,019 · Granted Jul 17, 2018

Animal treatments

Inventors: David Rock (Hillsborough, NJ); Mark Ridall (Princeton, NJ)
Assignee: NEW MARKET PHARMACEUTICALS, LLC
A61K31/4439A61K9/0053A61K31/135A61K31/137A61K31/155A61K31/341A61K31/403A61K31/4164A61K31/4174A61K31/44A61K31/5415A61K31/635A61K31/7048C07D307/52C07D401/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,022,361
App. No.
14/275,019
Granted
Jul 17, 2018
Kind
B2
Abstract

Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.

Claims (12)

1. A freeze-dried Direct Systemic Induction (DSI) composition comprising:

the free acid of flunixin;

wherein the DSI composition has an oral dissolution time of less than about 75 seconds.

2. The freeze-dried DSI composition of claim 1 , wherein the oral dissolution time is less than about 5 seconds.

3. The freeze-dried DSI composition of claim 1 , wherein the free acid of flunixin is present in an amount ranging from about 0.5% to about 50% by weight of the overall composition.

4. The freeze-dried DSI composition of claim 1 , wherein the composition comprises one or more excipients.

5. A method of treating pain in an animal in need thereof, comprising:

administering to said animal, a freeze-dried DSI composition of claim 1 .

6. The method of claim 5 , wherein the animal is an equine.

7. The method of claim 5 , wherein the freeze-dried DSI composition is administered to the oral cavity of the animal.

8. The freeze-dried DSI composition of claim 4 , wherein at least one excipient is gelatin.

9. The method of claim 5 , wherein the greater than 50% of the administered flunixin is absorbed into the animal's circulatory system through the pre-gastric mucosal cells lining the animal's alimentary canal.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2019
From: RIDALL, MARK
To: NEWMARKET PHARMACEUTICALS LLC
Reel/Frame 050714/0474 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2019
From: ROCK, DAVID; RIDALL, MARK
To: NEWMARKET PHARMACEUTICALS LLC
Reel/Frame 050714/0400 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PRTY TO NEWMARKET PHARMACEUTICALS LLC AND RECEIVING PRTY TO VETBRIDGE PRODUCT DEVELOPMENT SUBSIDIARY I (NM-OMP), LLC PREVIOUSLY RECORDED ON REEL 047254 FRAME 0898. ASSIGNOR(S) HEREBY CONFIRMS THE THE EXCLUSIVE DISTRIBUTION AND LICENSE AGREEMENT.. Recorded Jul 26, 2019
From: NEWMARKET PHARMACEUTICALS LLC
To: VETBRIDGE PRODUCT DEVELOPMENT SUBSIDIARY I (NM-OMP), LLC
Reel/Frame 049888/0847 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE PATENT NO: PREVIOUSLY RECORDED AT REEL: 046924 FRAME: 0600. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 28, 2019
From: NEWMARKET PHARMACEUTICALS LLC
To: RIDALL, MARK
Reel/Frame 048467/0351 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2018
From: NEWMARKET PHARMACEUTICALS LLC
To: RIDALL, MARK
Reel/Frame 046924/0600 →
EXCLUSIVE DISTRIBUTION AND LICENSE AGREEMENT Recorded Jul 17, 2018
From: VETBRIDGE PRODUCT DEVELOPMENT SUBSIDIARY
To: NEWMARKET PHARMACEUTICALS LLC
Reel/Frame 047254/0898 →
CONVERTIBLE PROMISSORY NOTE Recorded Sep 27, 2017
From: NEW MARKET PHARMACEUTICALS, LLC
To: RIDALL, MARK
Reel/Frame 044029/0113 →
LICENSE Recorded Oct 10, 2014
From: NEW MARKET PHARMACEUTICALS, LLC
To: VETBRIDGE PRODUCT DEVELOPMENT SUBSIDIARY I, LLC
Reel/Frame 033930/0226 →
Continuity (4)
Continuation 13343692 · Jan 4, 2012
Provisional Application 61437763 · Jan 31, 2011
Related Publication 20150018293A1 · Jan 15, 2015
Related Publication 20160095825A9 · Apr 7, 2016
Cited By (2)
US 12,496,295 US 12,653,812